CoChat

Butyrate confers colorectal cancer cell resistance to anti-PD-1 therapy by promoting CPT1A-mediated fatty acid oxidation

Open access
Zhu, Ran, Gu, Shujiang, Tao, Yuan, Zhang, Yan · 2025 · Discover Oncology

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Immunotherapy including anti-PD-1 demonstrated therapeutic promise to colorectal cancer (CRC) patients, but tumor cell resistance limits their efficacy. Butyrate may influence therapeutic outcomes by modulating tumor metabolism, but it remains unclear whether butyrate influences CRC cell resistance to anti-PD-1 therapy. We aimed to investigate whether butyrate promotes resistance to anti-PD-1 therapy in CRC and underlying metabolic and immunologic mechanisms. CRC murine models were established by subcutaneously inoculating MC38 cells or butyrate/anti-PD-1-administered tumor cells of mice, followed by treatment with butyrate, anti-PD-1, or a combination. Therapeutic efficacy was assessed by tumor growth and survival outcomes. In vitro, HCT116 cells were exposed to monotherapy or co-therapy regimens. Carnitine Palmitoyltransferase 1A (CPT1A) knockdown was conducted by shRNA transfection both in vivo and in vitro. Fatty acid oxidation (FAO) was determined by oxygen consumption rate and CPT1A expression. CD8+ T cell cytotoxicity assays and CD8 expression in tumors were performed to evaluate immune cell infiltration. The addition of butyrate into anti-PD-1 treatment combination did not improve survival or reduce tumor volume compared to anti-PD-1 alone, with a marked activation of CPT1A observed in treated tumor tissues. Butyrate significantly elevated FAO, contributing to elevated oxygen consumption rate and reduced CD8+ T cell cytotoxicity. However, in sh-CPT1A models, the combination therapy significantly improved antitumor efficacy and restored CD8+ T cell infiltration. Furthermore, CRC patient samples resistant to anti-PD-1 therapy exhibited elevated CPT1A levels. Butyrate-induced CPT1A-mediated FAO promotes resistance to anti-PD-1 therapy in CRC, suggesting that targeting CPT1A might enhance the efficacy of immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12672-025-02686-x

Cites

Statistics

Figures

Fig. 1 Butyrate/α-PD1 combination did not improve antitumor efficacy in colorectal cancer murine models. After successful subcutaneous inoculation with MC38 cells to establish the colorectal cancer model, mice were administered butyrate, α-PD1 alone, or in combination, with saline and IgG injections used as the control. A Tumor volumes were measured every 5 days. Tumor size threshold for ethical euthanasia was set at 2000 mm3 or upon detection of severe ulceration. B Survival curves were generated until the ethical end or 60 days from treatment
Fig. 1 Butyrate/α-PD1 combination did not improve antitumor efficacy in colorectal cancer murine models. After successful subcutaneous inoculation with MC38 cells to establish the colorectal cancer model, mice were administered butyrate, α-PD1 alone, or in combination, with saline and IgG injections used as the control. A Tumor volumes were measured every 5 days. Tumor size threshold for ethical euthanasia was set at 2000 mm3 or upon detection of severe ulceration. B Survival curves were generated until the ethical end or 60 days from treatmentCC BY-NC-ND · PubMed Central
Fig. 2 Butyrate/α-PD1 combination induces anti-PD-1 therapy resistance and CPT1A activation in colorectal tumor tissues. A Schematic of experimental design. Tumor cells isolated from mice treated with Butyrate/α-PD1 combination therapy (Butyrate/α-PD1 MC38 cells) were inoculated subcutaneously into naive mice, with original MC38 cells injected as a control. After the transplanted tumor model was established, mice treated with IgG or α-PD1 for 28 days, at which B tumor images, C tumor volumes and D weight were assessed. E Western blot analysis was conducted to determine CPT1A and CPT1B protein expression. F Immunohistochemistry analysis was used for CPT1A expression evaluation in tumor tissues, with images captured at a magnification of 200× . Data are presented as mean ± SEM. *p < 0.05, ***p < 0.001
Fig. 2 Butyrate/α-PD1 combination induces anti-PD-1 therapy resistance and CPT1A activation in colorectal tumor tissues. A Schematic of experimental design. Tumor cells isolated from mice treated with Butyrate/α-PD1 combination therapy (Butyrate/α-PD1 MC38 cells) were inoculated subcutaneously into naive mice, with original MC38 cells injected as a control. After the transplanted tumor model was established, mice treated with IgG or α-PD1 for 28 days, at which B tumor images, C tumor volumes and D weight were assessed. E Western blot analysis was conducted to determine CPT1A and CPT1B protein expression. F Immunohistochemistry analysis was used for CPT1A expression evaluation in tumor tissues, with images captured at a magnification of 200× . Data are presented as mean ± SEM. *p < 0.05, ***p < 0.001CC BY-NC-ND · PubMed Central
Fig. 3 Butyrate enhances CPT1A-mediated fatty acid oxidation (FAO) and reduces α-PD1-induced cytotoxicity in vitro. HCT116 cells were treated with 5 mM butyrate for 6 h. After that, A Oxygen consumption rate (OCR), B CPT1A and CPT1B protein expression were determined by Seahorse XF24 extracellular flux analyzer and Western blot analysis, respectively. CD8+ T cells were co-cultured with HCT116 cells at a ratio of 10:1. Following 24-h treatment with α-PD1, butyrate, or their combination, C cytotoxicity was assessed via 2-h CCK-8 exposure. Subsequently, sh-NC and two types of sh-CPT1A were transfected to HCT116 cells. D CPT1A mRNA and E protein levels were determined by quantitative PCR and Western blotting, respectively, to evaluate transfection efficiency. sh2-CPT1A with a higher transfection efficiency was selected for further assays. F OCR assessment in CPT1A knockdown cells and (G) cytotoxicity assay in those co-cultured with CD8+ T cells prior to being treated with distinct therapies were conducted to evaluate FAO activation and capability of immune cells. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 3 Butyrate enhances CPT1A-mediated fatty acid oxidation (FAO) and reduces α-PD1-induced cytotoxicity in vitro. HCT116 cells were treated with 5 mM butyrate for 6 h. After that, A Oxygen consumption rate (OCR), B CPT1A and CPT1B protein expression were determined by Seahorse XF24 extracellular flux analyzer and Western blot analysis, respectively. CD8+ T cells were co-cultured with HCT116 cells at a ratio of 10:1. Following 24-h treatment with α-PD1, butyrate, or their combination, C cytotoxicity was assessed via 2-h CCK-8 exposure. Subsequently, sh-NC and two types of sh-CPT1A were transfected to HCT116 cells. D CPT1A mRNA and E protein levels were determined by quantitative PCR and Western blotting, respectively, to evaluate transfection efficiency. sh2-CPT1A with a higher transfection efficiency was selected for further assays. F OCR assessment in CPT1A knockdown cells and (G) cytotoxicity assay in those co-cultured with CD8+ T cells prior to being treated with distinct therapies were conducted to evaluate FAO activation and capability of immune cells. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001CC BY-NC-ND · PubMed Central
Fig. 4 CPT1A upregulation correlates with resistance to anti-PD-1 therapy in colorectal cancer (CRC) patients. Tumor tissues from CRC patients treated with Nivolumab were collected to assess A CPT1A mRNA levels, and B, C protein expression via quantitative PC, immunohistochemistry and Western blot analysis, respectively. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01. PD-1 S: PD-1 sensitive, n = 5; PD-1 R: PD-1 resistant, n = 4
Fig. 4 CPT1A upregulation correlates with resistance to anti-PD-1 therapy in colorectal cancer (CRC) patients. Tumor tissues from CRC patients treated with Nivolumab were collected to assess A CPT1A mRNA levels, and B, C protein expression via quantitative PC, immunohistochemistry and Western blot analysis, respectively. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01. PD-1 S: PD-1 sensitive, n = 5; PD-1 R: PD-1 resistant, n = 4CC BY-NC-ND · PubMed Central
Fig. 5 CPT1A deficiency improves the antitumor efficacy of butyrate/α-PD1 combination therapy in colorectal cancer mice. Mice were subcutaneously inoculated with sh-NC or sh-CPT1A-tranfected MC38 cells to establish the colorectal cancer model. Butyrate, α-PD1, or butyrate/α-PD1 combination were used for 28-day therapy. A Tumor volume progression was measured every three days. After treatment, tumors were collected to take B representative images and determine C tumor weight. D Immunofluorescence staining was performed to evaluate CD8+ T cell infiltration, CD8 + cells are stained in red, and nuclei are counterstained with DAPI (blue). Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. ns no significance
Fig. 5 CPT1A deficiency improves the antitumor efficacy of butyrate/α-PD1 combination therapy in colorectal cancer mice. Mice were subcutaneously inoculated with sh-NC or sh-CPT1A-tranfected MC38 cells to establish the colorectal cancer model. Butyrate, α-PD1, or butyrate/α-PD1 combination were used for 28-day therapy. A Tumor volume progression was measured every three days. After treatment, tumors were collected to take B representative images and determine C tumor weight. D Immunofluorescence staining was performed to evaluate CD8+ T cell infiltration, CD8 + cells are stained in red, and nuclei are counterstained with DAPI (blue). Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. ns no significanceCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 35 · Cited by 8

Metadata

Authors
Zhu, R., Gu, S., Tao, Y., & Zhang, Y.
Corresponding author
Zhang, Yan
Venue
Discover Oncology
Published
2025-05-27
Volume
16
Issue
1
Pages
935-935
ISSN
2730-6011 (ISSN-L)
OpenAlex
W4410787038
Cited by
8
References
35
Citations by year
2026: 5 · 2025: 3
FWCI
3.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Discover Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
butyrate, colorectal cancer, anti-PD-1 therapy, immunotherapy resistance, CPT1A, fatty acid oxidation, cancer metabolism, CD8+ T cell cytotoxicity, CD8+ T cell infiltration, combination therapy, HCT116 cells, MC38 cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Butyrate confers colorectal cancer cell resistance to anti-PD-1 therapy by promoting CPT1A-mediated fatty acid oxidation. https://app.cochat.ai/papers/10.1007/s12672-025-02686-x
The paper
Zhu, R., Gu, S., Tao, Y., & Zhang, Y. (2025). Butyrate confers colorectal cancer cell resistance to anti-PD-1 therapy by promoting CPT1A-mediated fatty acid oxidation. Discover Oncology. https://doi.org/10.1007/s12672-025-02686-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.